Global Lung Cancer Molecular Diagnostics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 178927
  • calendar_today Published On: Mar, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Lung Cancer Molecular Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Lung Cancer Molecular Diagnostics size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Lung Cancer Molecular Diagnostics market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Lung Cancer Molecular Diagnostics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

PCR

FISH

DNA Sequencing

Gene Chip

Market segment by Application, can be divided into

Clinical Diagnosis

Drug Screening

Research

Market segment by players, this report covers

Foundationmedicine

Roche

Qiagen

Liferiver

Tellgen

Genetech

Gpmedical

Sansure

Amoydx

Mole

Annoroad

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Lung Cancer Molecular Diagnostics

1.2 Classification of Lung Cancer Molecular Diagnostics by Type

1.2.1 Overview: Global Lung Cancer Molecular Diagnostics Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Lung Cancer Molecular Diagnostics Revenue Market Share by Type in 2020

1.2.3 PCR

1.2.4 FISH

1.2.5 DNA Sequencing

1.2.6 Gene Chip

1.3 Global Lung Cancer Molecular Diagnostics Market by Application

1.3.1 Overview: Global Lung Cancer Molecular Diagnostics Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Clinical Diagnosis

1.3.3 Drug Screening

1.3.4 Research

1.4 Global Lung Cancer Molecular Diagnostics Market Size & Forecast

1.5 Global Lung Cancer Molecular Diagnostics Market Size and Forecast by Region

1.5.1 Global Lung Cancer Molecular Diagnostics Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Lung Cancer Molecular Diagnostics Market Size by Region, (2016-2021)

1.5.3 North America Lung Cancer Molecular Diagnostics Market Size and Prospect (2016-2026)

1.5.4 Europe Lung Cancer Molecular Diagnostics Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Lung Cancer Molecular Diagnostics Market Size and Prospect (2016-2026)

1.5.6 South America Lung Cancer Molecular Diagnostics Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Lung Cancer Molecular Diagnostics Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Lung Cancer Molecular Diagnostics Market Drivers

1.6.2 Lung Cancer Molecular Diagnostics Market Restraints

1.6.3 Lung Cancer Molecular Diagnostics Trends Analysis

2 Company Profiles

2.1 Foundationmedicine

2.1.1 Foundationmedicine Details

2.1.2 Foundationmedicine Major Business

2.1.3 Foundationmedicine Lung Cancer Molecular Diagnostics Product and Solutions

2.1.4 Foundationmedicine Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Foundationmedicine Recent Developments and Future Plans

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche Lung Cancer Molecular Diagnostics Product and Solutions

2.2.4 Roche Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Roche Recent Developments and Future Plans

2.3 Qiagen

2.3.1 Qiagen Details

2.3.2 Qiagen Major Business

2.3.3 Qiagen Lung Cancer Molecular Diagnostics Product and Solutions

2.3.4 Qiagen Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Qiagen Recent Developments and Future Plans

2.4 Liferiver

2.4.1 Liferiver Details

2.4.2 Liferiver Major Business

2.4.3 Liferiver Lung Cancer Molecular Diagnostics Product and Solutions

2.4.4 Liferiver Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Liferiver Recent Developments and Future Plans

2.5 Tellgen

2.5.1 Tellgen Details

2.5.2 Tellgen Major Business

2.5.3 Tellgen Lung Cancer Molecular Diagnostics Product and Solutions

2.5.4 Tellgen Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Tellgen Recent Developments and Future Plans

2.6 Genetech

2.6.1 Genetech Details

2.6.2 Genetech Major Business

2.6.3 Genetech Lung Cancer Molecular Diagnostics Product and Solutions

2.6.4 Genetech Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Genetech Recent Developments and Future Plans

2.7 Gpmedical

2.7.1 Gpmedical Details

2.7.2 Gpmedical Major Business

2.7.3 Gpmedical Lung Cancer Molecular Diagnostics Product and Solutions

2.7.4 Gpmedical Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Gpmedical Recent Developments and Future Plans

2.8 Sansure

2.8.1 Sansure Details

2.8.2 Sansure Major Business

2.8.3 Sansure Lung Cancer Molecular Diagnostics Product and Solutions

2.8.4 Sansure Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Sansure Recent Developments and Future Plans

2.9 Amoydx

2.9.1 Amoydx Details

2.9.2 Amoydx Major Business

2.9.3 Amoydx Lung Cancer Molecular Diagnostics Product and Solutions

2.9.4 Amoydx Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Amoydx Recent Developments and Future Plans

2.10 Mole

2.10.1 Mole Details

2.10.2 Mole Major Business

2.10.3 Mole Lung Cancer Molecular Diagnostics Product and Solutions

2.10.4 Mole Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Mole Recent Developments and Future Plans

2.11 Annoroad

2.11.1 Annoroad Details

2.11.2 Annoroad Major Business

2.11.3 Annoroad Lung Cancer Molecular Diagnostics Product and Solutions

2.11.4 Annoroad Lung Cancer Molecular Diagnostics Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Annoroad Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Lung Cancer Molecular Diagnostics Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Lung Cancer Molecular Diagnostics Players Market Share

3.2.2 Top 10 Lung Cancer Molecular Diagnostics Players Market Share

3.2.3 Market Competition Trend

3.3 Lung Cancer Molecular Diagnostics Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Lung Cancer Molecular Diagnostics Revenue and Market Share by Type (2016-2021)

4.2 Global Lung Cancer Molecular Diagnostics Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Lung Cancer Molecular Diagnostics Revenue Market Share by Application (2016-2021)

5.2 Lung Cancer Molecular Diagnostics Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Lung Cancer Molecular Diagnostics Revenue by Type (2016-2026)

6.2 North America Lung Cancer Molecular Diagnostics Revenue by Application (2016-2026)

6.3 North America Lung Cancer Molecular Diagnostics Market Size by Country

6.3.1 North America Lung Cancer Molecular Diagnostics Revenue by Country (2016-2026)

6.3.2 United States Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

6.3.3 Canada Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

6.3.4 Mexico Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Lung Cancer Molecular Diagnostics Revenue by Type (2016-2026)

7.2 Europe Lung Cancer Molecular Diagnostics Revenue by Application (2016-2026)

7.3 Europe Lung Cancer Molecular Diagnostics Market Size by Country

7.3.1 Europe Lung Cancer Molecular Diagnostics Revenue by Country (2016-2026)

7.3.2 Germany Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

7.3.3 France Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

7.3.5 Russia Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

7.3.6 Italy Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Type (2016-2026)

8.2 Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Application (2016-2026)

8.3 Asia-Pacific Lung Cancer Molecular Diagnostics Market Size by Region

8.3.1 Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Region (2016-2026)

8.3.2 China Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

8.3.3 Japan Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

8.3.4 South Korea Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

8.3.5 India Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

8.3.7 Australia Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Lung Cancer Molecular Diagnostics Revenue by Type (2016-2026)

9.2 South America Lung Cancer Molecular Diagnostics Revenue by Application (2016-2026)

9.3 South America Lung Cancer Molecular Diagnostics Market Size by Country

9.3.1 South America Lung Cancer Molecular Diagnostics Revenue by Country (2016-2026)

9.3.2 Brazil Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

9.3.3 Argentina Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Type (2016-2026)

10.2 Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Application (2016-2026)

10.3 Middle East & Africa Lung Cancer Molecular Diagnostics Market Size by Country

10.3.1 Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Country (2016-2026)

10.3.2 Turkey Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

10.3.4 UAE Lung Cancer Molecular Diagnostics Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Lung Cancer Molecular Diagnostics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Lung Cancer Molecular Diagnostics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Lung Cancer Molecular Diagnostics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Lung Cancer Molecular Diagnostics Revenue (USD Million) by Region (2016-2021)

Table 5. Global Lung Cancer Molecular Diagnostics Revenue Market Share by Region (2021-2026)

Table 6. Foundationmedicine Corporate Information, Head Office, and Major Competitors

Table 7. Foundationmedicine Major Business

Table 8. Foundationmedicine Lung Cancer Molecular Diagnostics Product and Solutions

Table 9. Foundationmedicine Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Roche Corporate Information, Head Office, and Major Competitors

Table 11. Roche Major Business

Table 12. Roche Lung Cancer Molecular Diagnostics Product and Solutions

Table 13. Roche Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Qiagen Corporate Information, Head Office, and Major Competitors

Table 15. Qiagen Major Business

Table 16. Qiagen Lung Cancer Molecular Diagnostics Product and Solutions

Table 17. Qiagen Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Liferiver Corporate Information, Head Office, and Major Competitors

Table 19. Liferiver Major Business

Table 20. Liferiver Lung Cancer Molecular Diagnostics Product and Solutions

Table 21. Liferiver Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Tellgen Corporate Information, Head Office, and Major Competitors

Table 23. Tellgen Major Business

Table 24. Tellgen Lung Cancer Molecular Diagnostics Product and Solutions

Table 25. Tellgen Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Genetech Corporate Information, Head Office, and Major Competitors

Table 27. Genetech Major Business

Table 28. Genetech Lung Cancer Molecular Diagnostics Product and Solutions

Table 29. Genetech Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Gpmedical Corporate Information, Head Office, and Major Competitors

Table 31. Gpmedical Major Business

Table 32. Gpmedical Lung Cancer Molecular Diagnostics Product and Solutions

Table 33. Gpmedical Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Sansure Corporate Information, Head Office, and Major Competitors

Table 35. Sansure Major Business

Table 36. Sansure Lung Cancer Molecular Diagnostics Product and Solutions

Table 37. Sansure Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Amoydx Corporate Information, Head Office, and Major Competitors

Table 39. Amoydx Major Business

Table 40. Amoydx Lung Cancer Molecular Diagnostics Product and Solutions

Table 41. Amoydx Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Mole Corporate Information, Head Office, and Major Competitors

Table 43. Mole Major Business

Table 44. Mole Lung Cancer Molecular Diagnostics Product and Solutions

Table 45. Mole Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Annoroad Corporate Information, Head Office, and Major Competitors

Table 47. Annoroad Major Business

Table 48. Annoroad Lung Cancer Molecular Diagnostics Product and Solutions

Table 49. Annoroad Lung Cancer Molecular Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Global Lung Cancer Molecular Diagnostics Revenue (USD Million) by Players (2019-2021)

Table 51. Global Lung Cancer Molecular Diagnostics Revenue Share by Players (2019-2021)

Table 52. Breakdown of Lung Cancer Molecular Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 53. Lung Cancer Molecular Diagnostics Players Head Office, Products and Services Provided

Table 54. Lung Cancer Molecular Diagnostics Mergers & Acquisitions in the Past Five Years

Table 55. Lung Cancer Molecular Diagnostics New Entrants and Expansion Plans

Table 56. Global Lung Cancer Molecular Diagnostics Revenue (USD Million) by Type (2016-2021)

Table 57. Global Lung Cancer Molecular Diagnostics Revenue Share by Type (2016-2021)

Table 58. Global Lung Cancer Molecular Diagnostics Revenue Forecast by Type (2021-2026)

Table 59. Global Lung Cancer Molecular Diagnostics Revenue by Application (2016-2021)

Table 60. Global Lung Cancer Molecular Diagnostics Revenue Forecast by Application (2021-2026)

Table 61. North America Lung Cancer Molecular Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 62. North America Lung Cancer Molecular Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 63. North America Lung Cancer Molecular Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 64. North America Lung Cancer Molecular Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 65. North America Lung Cancer Molecular Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 66. North America Lung Cancer Molecular Diagnostics Revenue by Country (2021-2026) & (USD Million)

Table 67. Europe Lung Cancer Molecular Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 68. Europe Lung Cancer Molecular Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 69. Europe Lung Cancer Molecular Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 70. Europe Lung Cancer Molecular Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 71. Europe Lung Cancer Molecular Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 72. Europe Lung Cancer Molecular Diagnostics Revenue by Country (2021-2026) & (USD Million)

Table 73. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 74. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 75. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 76. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 77. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Region (2016-2021) & (USD Million)

Table 78. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue by Region (2021-2026) & (USD Million)

Table 79. South America Lung Cancer Molecular Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 80. South America Lung Cancer Molecular Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 81. South America Lung Cancer Molecular Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 82. South America Lung Cancer Molecular Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 83. South America Lung Cancer Molecular Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 84. South America Lung Cancer Molecular Diagnostics Revenue by Country (2021-2026) & (USD Million)

Table 85. Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Type (2016-2021) & (USD Million)

Table 86. Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Type (2021-2026) & (USD Million)

Table 87. Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Application (2016-2021) & (USD Million)

Table 88. Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Application (2021-2026) & (USD Million)

Table 89. Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Country (2016-2021) & (USD Million)

Table 90. Middle East & Africa Lung Cancer Molecular Diagnostics Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Lung Cancer Molecular Diagnostics Picture

Figure 2. Global Lung Cancer Molecular Diagnostics Revenue Market Share by Type in 2020

Figure 3. PCR

Figure 4. FISH

Figure 5. DNA Sequencing

Figure 6. Gene Chip

Figure 7. Lung Cancer Molecular Diagnostics Revenue Market Share by Application in 2020

Figure 8. Clinical Diagnosis Picture

Figure 9. Drug Screening Picture

Figure 10. Research Picture

Figure 11. Global Lung Cancer Molecular Diagnostics Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 12. Global Lung Cancer Molecular Diagnostics Revenue and Forecast (2016-2026) & (USD Million)

Figure 13. Global Lung Cancer Molecular Diagnostics Revenue Market Share by Region (2016-2026)

Figure 14. Global Lung Cancer Molecular Diagnostics Revenue Market Share by Region in 2020

Figure 15. North America Lung Cancer Molecular Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Europe Lung Cancer Molecular Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. South America Lung Cancer Molecular Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Middle East and Africa Lung Cancer Molecular Diagnostics Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Lung Cancer Molecular Diagnostics Market Drivers

Figure 21. Lung Cancer Molecular Diagnostics Market Restraints

Figure 22. Lung Cancer Molecular Diagnostics Market Trends

Figure 23. Foundationmedicine Recent Developments and Future Plans

Figure 24. Roche Recent Developments and Future Plans

Figure 25. Qiagen Recent Developments and Future Plans

Figure 26. Liferiver Recent Developments and Future Plans

Figure 27. Tellgen Recent Developments and Future Plans

Figure 28. Genetech Recent Developments and Future Plans

Figure 29. Gpmedical Recent Developments and Future Plans

Figure 30. Sansure Recent Developments and Future Plans

Figure 31. Amoydx Recent Developments and Future Plans

Figure 32. Mole Recent Developments and Future Plans

Figure 33. Annoroad Recent Developments and Future Plans

Figure 34. Global Lung Cancer Molecular Diagnostics Revenue Share by Players in 2020

Figure 35. Lung Cancer Molecular Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 36. Global Top 3 Players Lung Cancer Molecular Diagnostics Revenue Market Share in 2020

Figure 37. Global Top 10 Players Lung Cancer Molecular Diagnostics Revenue Market Share in 2020

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 39. Global Lung Cancer Molecular Diagnostics Revenue Share by Type in 2020

Figure 40. Global Lung Cancer Molecular Diagnostics Market Share Forecast by Type (2021-2026)

Figure 41. Global Lung Cancer Molecular Diagnostics Revenue Share by Application in 2020

Figure 42. Global Lung Cancer Molecular Diagnostics Market Share Forecast by Application (2021-2026)

Figure 43. North America Lung Cancer Molecular Diagnostics Sales Market Share by Type (2016-2026)

Figure 44. North America Lung Cancer Molecular Diagnostics Sales Market Share by Application (2016-2026)

Figure 45. North America Lung Cancer Molecular Diagnostics Revenue Market Share by Country (2016-2026)

Figure 46. United States Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Canada Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 48. Mexico Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 49. Europe Lung Cancer Molecular Diagnostics Sales Market Share by Type (2016-2026)

Figure 50. Europe Lung Cancer Molecular Diagnostics Sales Market Share by Application (2016-2026)

Figure 51. Europe Lung Cancer Molecular Diagnostics Revenue Market Share by Country (2016-2026)

Figure 52. Germany Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. France Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. United Kingdom Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Russia Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 56. Italy Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Asia-Pacific Lung Cancer Molecular Diagnostics Sales Market Share by Type (2016-2026)

Figure 58. Asia-Pacific Lung Cancer Molecular Diagnostics Sales Market Share by Application (2016-2026)

Figure 59. Asia-Pacific Lung Cancer Molecular Diagnostics Revenue Market Share by Region (2016-2026)

Figure 60. China Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Japan Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. South Korea Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. India Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Southeast Asia Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 65. Australia Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. South America Lung Cancer Molecular Diagnostics Sales Market Share by Type (2016-2026)

Figure 67. South America Lung Cancer Molecular Diagnostics Sales Market Share by Application (2016-2026)

Figure 68. South America Lung Cancer Molecular Diagnostics Revenue Market Share by Country (2016-2026)

Figure 69. Brazil Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Argentina Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Middle East and Africa Lung Cancer Molecular Diagnostics Sales Market Share by Type (2016-2026)

Figure 72. Middle East and Africa Lung Cancer Molecular Diagnostics Sales Market Share by Application (2016-2026)

Figure 73. Middle East and Africa Lung Cancer Molecular Diagnostics Revenue Market Share by Country (2016-2026)

Figure 74. Turkey Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Saudi Arabia Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. UAE Lung Cancer Molecular Diagnostics Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source